Erudio Healtherudio.com
Sponsor
AstraZeneca trials: what clinicians said in public
HCP commentary reports on 4 clinical trials sponsored by AstraZeneca: ARTEMIDE-01, DURGA-6, eVOLVE-Lung02 and VIOLETTE. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 103 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (AstraZeneca; Acerta Pharma BV; Alexion Pharmaceuticals, Inc.; MedImmune LLC). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| VIOLETTE NCT03330847 · AstraZeneca | metastatic triple-negative breast cancer | Phase 2 | 24 | 6 | Focused | Nov 19, 2026 | Preview |
| DURGA-6 NCT07735637 · AstraZeneca | transplant-eligible newly diagnosed multiple myeloma | Phase 3 | 61 | 4 | Focused | Oct 30, 2026 | Preview |
| eVOLVE-Lung02 NCT05984277 · AstraZeneca | first-line metastatic non-small cell lung cancer | Phase 3 | 37 | 10 | Focused | Oct 29, 2026 | Preview |
| ARTEMIDE-01 NCT04995523 · AstraZeneca | advanced or metastatic NSCLC | Phase 1/Phase 2 | 53 | 15 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ADAURA NCT02511106 · AstraZeneca DeepView → | EGFR mutation-positive stage IB-IIIA non-small cell lung cancer | Phase 3 | Deep | View | |||
| FLAURA2 NCT04035486 · AstraZeneca DeepView → | first-line EGFR-mutated advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| VOLGA NCT04960709 · AstraZeneca DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| ADRIATIC NCT03703297 · AstraZeneca DeepView → | limited-stage small-cell lung cancer after concurrent chemoradiotherapy | Phase 3 | Deep | View | |||
| DESTINY-Breast11 NCT05113251 · AstraZeneca DeepView → | high-risk HER2-positive early-stage breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast06 NCT04494425 · AstraZeneca DeepView → | hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer | Phase 3 | Deep | View | |||
| AEGEAN NCT03800134 · AstraZeneca DeepView → | resectable stages II and III non-small cell lung cancer | Phase 3 | Deep | View | |||
| TROPION-Breast02 NCT05374512 · AstraZeneca DeepView → | first-line inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast09 NCT04784715 · AstraZeneca DeepView → | first-line HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| FLAURA NCT02296125 · AstraZeneca DeepView → | first-line EGFR-mutated advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| CAPItello-291 NCT04305496 · AstraZeneca DeepView → | HR+/HER2- locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-PanTumor02 NCT04482309 · AstraZeneca DeepView → | HER2-expressing solid tumors | Phase 2 | Deep | View | |||
| TOPAZ-1 NCT03875235 · AstraZeneca DeepView → | first-line advanced biliary tract cancer | Phase 3 | Deep | View | |||
| POLO NCT02184195 · AstraZeneca DeepView → | germline BRCA-mutated metastatic pancreatic cancer | Phase 3 | Deep | View | |||
| DUO-E NCT04269200 · AstraZeneca DeepView → | newly diagnosed advanced or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| EMERALD-1 NCT03778957 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| EMERALD-3 NCT05301842 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| DESTINY-Lung04 NCT05048797 · AstraZeneca DeepView → | first-line HER2 exon 19/20-mutated advanced non-squamous NSCLC | Phase 3 | Deep | View | |||
| BEGONIA NCT03742102 · AstraZeneca DeepView → | first-line metastatic triple-negative breast cancer | Phase 1/Phase 2 | Deep | View | |||
| MDT-BRIDGE NCT05925530 · AstraZeneca DeepView → | resectable or borderline resectable stage IIB–IIIB NSCLC | Phase 2 | Deep | View | |||
| DESTINY-Breast12 NCT04739761 · AstraZeneca DeepView → | previously treated advanced/metastatic HER2-positive breast cancer | Phase 3 | Deep | View | |||
| SERENA-2 NCT04214288 · AstraZeneca DeepView → | ER-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| CLARITY-Gastric 01 NCT06346392 · AstraZeneca DeepView → | Claudin18.2-expressing advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| SERENA-4 NCT04711252 · AstraZeneca DeepView → | ER-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| OlympiAD NCT02000622 · AstraZeneca DeepView → | HER2-negative metastatic breast cancer with germline BRCA mutation | Phase 3 | Deep | View | |||
| NeoCOAST-2 NCT05061550 · AstraZeneca DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 2 | Deep | View | |||
| DESTINY-Gastric03 NCT04379596 · AstraZeneca DeepView → | advanced HER2-expressing gastric cancer | Phase 2 | Deep | View | |||
| DUO-O NCT03737643 · AstraZeneca DeepView → | newly diagnosed advanced ovarian cancer | Phase 3 | Deep | View | |||
| CAMBRIA-2 NCT05952557 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| IPASS NCT00322452 · AstraZeneca DeepView → | first-line advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| ELEVATE-TN NCT02475681 · Acerta Pharma BV DeepView → | previously untreated chronic lymphocytic leukemia | Phase 3 | Deep | View | |||
| CAMBRIA-1 NCT05774951 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| PACIFIC-4 NCT03833154 · AstraZeneca DeepView → | unresected stage I/II, lymph-node negative NSCLC | Phase 3 | Deep | View | |||
| SERENA-6 NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| ESCALADE NCT04529772 · Acerta Pharma BV DeepView → | previously untreated non-GCB diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| PACIFIC-9 NCT05221840 · AstraZeneca DeepView → | unresectable stage III non-small cell lung cancer | Phase 3 | Deep | View | |||
| TROPION-Breast05 NCT06103864 · AstraZeneca DeepView → | PD-L1-positive inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| NeoADAURA NCT04351555 · AstraZeneca DeepView → | resectable EGFR-mutated non-small cell lung cancer | Phase 3 | Deep | View | |||
| PACIFIC-6 NCT03693300 · AstraZeneca DeepView → | unresectable stage III non-small cell lung cancer | Phase 2 | Deep | View | |||
| CAPItello-292 NCT04862663 · AstraZeneca DeepView → | HR+/HER2- advanced breast cancer | Phase 3 | Deep | View | |||
| SAVOIR NCT03091192 · AstraZeneca DeepView → | MET-driven papillary renal cell carcinoma | Phase 3 | Deep | View | |||
| MATTERHORN NCT04592913 · AstraZeneca DeepView → | resectable gastric and gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| ADAURA2 NCT05120349 · AstraZeneca DeepView → | completely resected stage IA2-IA3 EGFR-mutated NSCLC | Phase 3 | Deep | View | |||
| TROPION-Breast03 NCT05629585 · AstraZeneca DeepView → | stage I-III triple-negative breast cancer with residual disease | Phase 3 | Deep | View | |||
| TROPION-Lung14 NCT06350097 · AstraZeneca DeepView → | first-line EGFR-mutated locally advanced or metastatic NSCLC | Phase 3 | Deep | View | |||
| AURA3 NCT02151981 · AstraZeneca DeepView → | EGFR T790M-positive advanced non-small-cell lung cancer | Phase 3 | Deep | View | |||
| MEDIOLA NCT02734004 · AstraZeneca DeepView → | advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| TROPION-Lung04 NCT04612751 · AstraZeneca DeepView → | advanced or metastatic non-small cell lung cancer | Phase 1 | Deep | View | |||
| TROPION-Lung15 NCT06417814 · AstraZeneca DeepView → | EGFR-mutated advanced non-small cell lung cancer after osimertinib | Phase 3 | Deep | View | |||
| DESTINY-Lung03 NCT04686305 · AstraZeneca DeepView → | first-line advanced or metastatic HER2-overexpressing non-squamous NSCLC | Phase 1 | Deep | View | |||
| NeoCOAST NCT03794544 · MedImmune LLC DeepView → | resectable early-stage non-small cell lung cancer | Phase 2 | Deep | View | |||
| DESTINY-Breast07 NCT04538742 · AstraZeneca DeepView → | HER2-positive metastatic breast cancer | Phase 1/Phase 2 | Deep | View | |||
| OReO NCT03106987 · AstraZeneca DeepView → | relapsed ovarian cancer previously treated with PARP inhibitor | Phase 3 | Deep | View | |||
| PACIFIC-5 NCT03706690 · AstraZeneca DeepView → | unresectable stage III NSCLC | Phase 3 | Deep | View | |||
| TROPION-Breast01 NCT05104866 · AstraZeneca DeepView → | previously treated inoperable/metastatic HR-positive, HER2-negative breast cancer | Phase 3 | Deep | View | |||
| SOLO3 NCT02282020 · AstraZeneca DeepView → | germline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer | Phase 3 | Deep | View | |||
| LATIFY NCT05450692 · AstraZeneca DeepView → | advanced or metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast08 NCT04556773 · AstraZeneca DeepView → | HER2-low metastatic breast cancer | Phase 1 | Deep | View | |||
| EMERALD-Y90 NCT06040099 · AstraZeneca DeepView → | unresectable hepatocellular carcinoma | Phase 2 | Deep | View | |||
| FONTANA NCT05797168 · AstraZeneca DeepView → | solid tumors | Phase 1/Phase 2 | Deep | View | |||
| BISCAY NCT02546661 · AstraZeneca DeepView → | Not given | Phase 1 | Deep | View | |||
| SERENA-1 NCT03616587 · AstraZeneca StandardView → | ER-positive, HER2-negative advanced breast cancer | Phase 1 | Standard | View | |||
| ELIOS NCT03239340 · AstraZeneca StandardView → | EGFR-mutant advanced non-small cell lung cancer | Phase 2 | Standard | View | |||
| LAURA NCT03521154 · AstraZeneca StandardView → | unresectable stage III EGFR-mutated non-small cell lung cancer | Phase 3 | Standard | View | |||
| CAPItello-281 NCT04493853 · AstraZeneca StandardView → | PTEN-deficient de novo metastatic hormone-sensitive prostate cancer | Phase 3 | Standard | View | |||
| PACIFIC-8 NCT05211895 · AstraZeneca StandardView → | stage III unresectable non-small cell lung cancer | Phase 3 | Standard | View | |||
| PACIFIC-2 NCT03519971 · AstraZeneca StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| MERMAID-1 NCT04385368 · AstraZeneca StandardView → | Not given | Phase 3 | Standard | View | |||
| NEOLA NCT06194448 · AstraZeneca StandardView → | EGFR mutation-positive stage III unresectable NSCLC | Phase 2 | Standard | View | |||
| EvoPAR-Prostate01 NCT06120491 · AstraZeneca StandardView → | metastatic castration-sensitive prostate cancer | Phase 3 | Standard | View | |||
| PATAPSCO NCT05943106 · AstraZeneca StandardView → | BCG-naïve, high-risk non-muscle-invasive bladder cancer | Phase 3 | Standard | View | |||
| DESTINY-BTC01 NCT06467357 · AstraZeneca StandardView → | first-line HER2-expressing advanced biliary tract cancer | Phase 3 | Standard | View | |||
| EvoPAR-Breast01 NCT06380751 · AstraZeneca StandardView → | first-line BRCA1/BRCA2/PALB2-mutated HR-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| ARTEMIDE-Gastric01 NCT06764875 · AstraZeneca StandardView → | first-line HER2-positive gastric or gastroesophageal junction cancer | Phase 3 | Standard | View | |||
| PACIFIC NCT02125461 · AstraZeneca StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| ORCHARD NCT03944772 · AstraZeneca StandardView → | EGFR-mutated advanced NSCLC after first-line osimertinib | Phase 2 | Standard | View | |||
| TRITON NCT06008093 · AstraZeneca StandardView → | first-line STK11/KEAP1/KRAS-mutated metastatic non-squamous NSCLC | Phase 2 | Standard | View | |||
| MERMAID-2 NCT04642469 · AstraZeneca FocusedView → | Not given | Phase 3 | Focused | View | |||
| SOUNDTRACK-B NCT06526793 · AstraZeneca FocusedView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 2 | Focused | View | |||
| HIMALAYA NCT03298451 · AstraZeneca FocusedView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Focused | View | |||
| NIAGARA NCT03732677 · AstraZeneca FocusedView → | muscle-invasive bladder cancer | Phase 3 | Focused | View | |||
| PROpel NCT03732820 · AstraZeneca FocusedView → | Not given | Phase 3 | Focused | View | |||
| TROPION-PanTumor03 NCT05489211 · AstraZeneca FocusedView → | advanced/metastatic solid tumors | Phase 2 | Focused | View | |||
| AVANZAR NCT05687266 · AstraZeneca FocusedView → | first-line advanced NSCLC without actionable genomic alterations | Phase 3 | Focused | View | |||
| SAFFRON NCT05261399 · AstraZeneca FocusedView → | EGFR-mutated, MET-overexpressed/amplified locally advanced or metastatic NSCLC | Phase 3 | Focused | View | |||
| TROPION-Lung17 NCT07291037 · AstraZeneca FocusedView → | TROP2-positive advanced/metastatic non-squamous NSCLC without actionable genomic alterations | Phase 3 | Focused | View | |||
| PROfound NCT02987543 · AstraZeneca FocusedView → | metastatic castration-resistant prostate cancer with HRR alterations | Phase 3 | Focused | View | |||
| SAVANNAH NCT03778229 · AstraZeneca FocusedView → | EGFR-mutated MET+ advanced NSCLC following progression on osimertinib | Phase 2 | Focused | View | |||
| CARES NCT04504825 · Alexion Pharmaceuticals, Inc. FocusedView → | treatment-naïve Mayo stage IIIb AL amyloidosis | Phase 3 | Focused | View | |||
| TROPION-PanTumor02 NCT05460273 · AstraZeneca FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| PRIMAVERA NCT06137144 · AstraZeneca FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| DANUBE NCT02516241 · AstraZeneca FocusedView → | first-line unresectable stage IV urothelial cancer | Phase 3 | Focused | View | |||
| CARES NCT04512235 · Alexion Pharmaceuticals, Inc. FocusedView → | treatment-naïve Mayo stage IIIa AL amyloidosis | Phase 3 | Focused | View | |||
| TARGET NCT05526755 · AstraZeneca FocusedView → | Not given | Phase 2 | Focused | View | |||
| CLARITY-PanTumour01 NCT06219941 · AstraZeneca FocusedView → | claudin 18.2-expressing advanced solid tumors | Phase 2 | Focused | View | |||
| ACE-CL-001 NCT02029443 · Acerta Pharma BV FocusedView → | chronic lymphocytic leukemia, Richter's syndrome or prolymphocytic leukemia | Phase 1/Phase 2 | Focused | View | |||
| ACE-LY-308 NCT02972840 · Acerta Pharma BV FocusedView → | previously untreated mantle cell lymphoma | Phase 3 | Focused | View | |||
| COAST NCT03822351 · MedImmune LLC FocusedView → | Not given | Phase 2 | Focused | View | |||
| TROPION-Urothelial04 NCT07720284 · AstraZeneca FocusedView → | Not given | Phase 3 | Focused | View | |||
| BAYOU NCT03459846 · AstraZeneca FocusedView → | previously untreated, platinum-ineligible metastatic urothelial carcinoma | Phase 2 | Focused | View | |||
| ORION NCT03775486 · AstraZeneca FocusedView → | stage IV non-small cell lung cancer | Phase 2 | Focused | View | |||
| COMPEL NCT04765059 · AstraZeneca FocusedView → | Not given | Phase 3 | Focused | View | |||
| SAMETA NCT05043090 · AstraZeneca FocusedView → | MET-driven unresectable locally advanced/metastatic papillary renal cell carcinoma | Phase 3 | Focused | View | |||